Aaron Iding and Colleagues on Additional Oxerutin Link to DVT
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”Additional oxerutin therapy to promote deep vein thrombus resolution (RESOLVE-DVT): a randomized controlled pilot trial
Oxerutin therapy alongside standard treatment reduced residual venous obstruction in deep vein thrombosis patients, potentially lowering postthrombotic syndrome risk compared to standard treatment alone.
Authors: Aaron Iding, Ruben Hupperetz, Rutger Brans, Hugo Ten cate, Daan van Twist, Arina J. Ten Cate-Hoek”
Read the full article here.
Article: Additional oxerutin therapy to promote deep vein thrombus resolution (RESOLVE-DVT): a randomized controlled pilot trial
Authors: Aaron Iding, Ruben D. Hupperetz, Rutger J. B. Brans, Hugo ten Cate, Daan J. L. van Twist, Arina J. ten Cate-Hoek
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 12, 2026, 22:12Maciej Banach: The ‘Metastatic’ Cardiovascular Threat We Can No Longer Ignore
-
Apr 12, 2026, 21:52Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
-
Apr 12, 2026, 21:37Demosthenes Panagiotakos: Hellenic Atherosclerosis Society Calls for Papers on Innovative Strategies in Atherosclerotic Plaque Management
-
Apr 12, 2026, 21:24Heghine Khachatryan: Diagnosing PNH in Resource-Limited Settings
-
Apr 12, 2026, 21:15Katariina Öörni: Role of Cholesterol Absorption Efficiency in Atherosclerosis
-
Apr 12, 2026, 17:34Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
-
Apr 12, 2026, 17:33Augustina Isioma Ikusemoro: ABO Typing Is Not the Same in Infants and Adults
-
Apr 12, 2026, 17:32Bastu Odoka: Same Blood Group Does Not Guarantee Compatibility
-
Apr 12, 2026, 17:31Jack Hadfield: SARS-CoV-2–Associated Lasting Mitochondrial Injury in Cardiomyocytes